This article was originally published in The Gray Sheet
A new nanotechnology-based testing platform for detecting and diagnosing the anthrax toxin developed at FDA is more sensitive than current anthrax-detection tests, such as the enzyme-linked immunosorbent assay (ELISA), recent data show. FDA's europium nanoparticle-based immunoassay (ENIA) detected the protective antigen (PA) anthrax protein in quantities 100 times lower than ELISA, and detected PA in 100% of samples of mouse plasma compared to 36.4% with ELISA, according to results of a proof-of-concept study in the March issue of Clinical and Vaccine Immunology. Author Indira Hewlett, Ph.D., chief of FDA's Laboratory of Molecular Virology, says the test could be further developed and refined by partners in academia or industry
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.